Achilles Therapeutics Announces Grant of European Patent Covering Use of Selectively Expanded T cells Targeting Clonal Neoantigens for the Treatment of Cancer
November 11, 2020 07:00 ET
|
Achilles Therapeutics
Achilles Therapeutics Announces Grant of European Patent Covering Use of Selectively Expanded T cells Targeting Clonal Neoantigens for the Treatment of Cancer - Related patent recently granted and...
Achilles Therapeutics appoints Carsten Boess to the Board of Directors
April 07, 2020 07:00 ET
|
Achilles Therapeutics
Achilles Therapeutics appoints Carsten Boess to the Board of Directors Stevenage, UK 7 April, 2020 – Achilles Therapeutics (“Achilles”), a clinical-stage oncology company developing personalised cell...
Achilles Therapeutics receives CTA Approval for Phase I/II Study in Metastatic or Recurrent Melanoma
February 13, 2019 07:00 ET
|
Achilles Therapeutics
Achilles Therapeutics receives CTA Approval for Phase I/II Study in Metastatic or Recurrent Melanoma Second CTA approval in 2019 – the first was for a NSCLC study Stevenage, UK 13 February...
Achilles Therapeutics receives CTA Approval for Phase I/II Study in Metastatic or Recurrent Melanoma
February 13, 2019 03:00 ET
|
Achilles Therapeutics
Achilles Therapeutics receives CTA Approval for Phase I/II Study in Metastatic or Recurrent Melanoma Second CTA approval in 2019 – the first was for a NSCLC study Stevenage, UK 13 February...